The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.

摘要: T-cell-mediated immune responses are typically low in conditions of malignant glioma which has been known to cause marked immunesuppression and dysregulate major T-cell signaling molecules. Thus, T-cell-based immunotherapies currently vogue the treatment glioma. The novel glycopeptide, T11TS/S-LFA-3/S-CD58 previously shown by our group be highly efficacious abrogation vivo vitro conditions. This glycopeptide ligands costimulatory CD2 molecule on T-cells, causing profound stimulation leading abrogation, suggesting probable involvement T11TS modulation pathway. present study offers a multi-targeted approach towards repair some key components immunological synapse at T-cell-APC interface is therefore first its kind offer holistic model restoration so as trigger T-cells activation against thus indicates that totally dysregulated molecular events restored back normal levels with administration T11TS, finally culminates abrogation. delineates an important whereby acts anti-neoplastic agent, helping chart out newer avenues fight gliomas.